Trail Ridge Investment Advisors LLC Takes Position in Cardinal Health, Inc. $CAH

Posted by Geri Gentry on Aug 25th, 2026

Trail Ridge Investment Advisors LLC purchased a new position in shares of Cardinal Health, Inc. (NYSE:CAH – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,474 shares of the company’s stock, valued at approximately $1,776,000. Cardinal Health comprises 0.8% of Trail Ridge Investment Advisors LLC’s investment portfolio, making the stock its 24th biggest holding.

Other hedge funds have also recently modified their holdings of the company. LWM Advisors Inc. increased its stake in Cardinal Health by 4.4% in the 2nd quarter. LWM Advisors Inc. now owns 1,028 shares of the company’s stock valued at $244,000 after buying an additional 43 shares during the period. Kathmere Capital Management LLC lifted its stake in shares of Cardinal Health by 1.2% in the 1st quarter. Kathmere Capital Management LLC now owns 4,242 shares of the company’s stock worth $896,000 after acquiring an additional 49 shares during the period. Hillsdale Investment Management Inc. boosted its holdings in shares of Cardinal Health by 0.9% in the fourth quarter. Hillsdale Investment Management Inc. now owns 5,760 shares of the company’s stock valued at $1,184,000 after acquiring an additional 50 shares in the last quarter. V Square Quantitative Management LLC increased its stake in shares of Cardinal Health by 2.6% during the first quarter. V Square Quantitative Management LLC now owns 2,002 shares of the company’s stock worth $423,000 after acquiring an additional 50 shares during the period. Finally, Generali Asset Management SPA SGR raised its holdings in Cardinal Health by 11.0% during the fourth quarter. Generali Asset Management SPA SGR now owns 513 shares of the company’s stock worth $105,000 after purchasing an additional 51 shares in the last quarter. 87.17% of the stock is owned by institutional investors and hedge funds.

Cardinal Health Trading Up 1.1%

CAH stock opened at $232.13 on Tuesday. The company has a market cap of $53.99 billion, a P/E ratio of 32.11, a P/E/G ratio of 1.23 and a beta of 0.49. Cardinal Health, Inc. has a 52 week low of $145.87 and a 52 week high of $258.30. The company’s 50-day moving average price is $232.13 and its 200 day moving average price is $217.96.

Cardinal Health (NYSE:CAH – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.42 by $0.49. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The company had revenue of $63.67 billion during the quarter, compared to analysts’ expectations of $65.15 billion. During the same period last year, the company posted $2.08 earnings per share. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. On average, equities research analysts expect that Cardinal Health, Inc. will post 12.54 earnings per share for the current year.

Cardinal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Thursday, October 1st will be issued a dividend of $0.5158 per share. The ex-dividend date of this dividend is Thursday, October 1st. This represents a $2.06 annualized dividend and a yield of 0.9%. Cardinal Health’s payout ratio is currently 28.49%.

More Cardinal Health News

Here are the key news stories impacting Cardinal Health this week:

Positive Sentiment: Cardinal Health’s specialty business remains a key growth driver, supporting the case for retaining CAH in portfolios. The company has also issued fiscal 2027 adjusted EPS guidance of $12.40–$12.60, broadly consistent with analyst expectations. Reasons to Retain Cardinal Health Stock in Your Portfolio for Now
Positive Sentiment: Recent coverage highlights Cardinal Health’s efforts to expand its healthcare reach, potentially creating additional growth opportunities beyond its core pharmaceutical distribution operations. Why Is Cardinal Health Expanding Its Healthcare Reach?
Positive Sentiment: Cardinal Health’s latest quarterly results provided support for the stock: earnings per share exceeded consensus estimates, while revenue increased year over year. The company’s medical and pharmaceutical services also remain central to its relative performance within the healthcare providers and services group. Winners and Losers of Q2: Cardinal Health vs. Healthcare Providers and Services Stocks

Insider Activity

In other news, CEO Deborah Weitzman sold 7,354 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $235.45, for a total value of $1,731,499.30. Following the completion of the transaction, the chief executive officer owned 77,901 shares in the company, valued at $18,341,790.45. This trade represents a 8.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jessica L. Mayer sold 29,436 shares of Cardinal Health stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $236.19, for a total value of $6,952,488.84. Following the transaction, the insider directly owned 33,076 shares of the company’s stock, valued at $7,812,220.44. This trade represents a 47.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 210,271 shares of company stock valued at $49,626,657 in the last 90 days. Insiders own 0.12% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. JPMorgan Chase & Co. raised their price objective on shares of Cardinal Health from $215.00 to $260.00 and gave the company a “neutral” rating in a research report on Thursday, August 13th. Wells Fargo & Company increased their target price on Cardinal Health from $245.00 to $277.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Mizuho raised their price target on Cardinal Health from $240.00 to $250.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Citigroup lifted their price target on Cardinal Health from $265.00 to $280.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings lowered Cardinal Health from a “buy (b+)” rating to a “buy (b)” rating in a report on Wednesday, August 19th. Sixteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $266.56.

Read Our Latest Stock Report on Cardinal Health

About Cardinal Health

(Free Report)

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.